Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
Stimuvax (emepepimut-S) is a peptide vaccine comprised of synthetic peptide based on Muc-1 protein, which may enhance immune response to Muc-1 expressing tumor cells (NCI Drug Dictionary).
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Emepepimut-S||Stimuvax|L-BLP25|BP1-7-KLH|tecemotide||Stimuvax (emepepimut-S) is a peptide vaccine comprised of synthetic peptide based on Muc-1 protein, which may enhance immune response to Muc-1 expressing tumor cells (PMID: 21689064.|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT00828009||Phase II||Cyclophosphamide Bevacizumab Paclitaxel Emepepimut-S Carboplatin||BLP25 Liposome Vaccine and Bevacizumab After Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery||Completed||USA||0|